U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

1997
189
Substance Class Protein
Created
by admin
on Mon Mar 31 18:48:10 GMT 2025
Edited
by admin
on Mon Mar 31 18:48:10 GMT 2025
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG1
Sequence Origin MOUSE CHIMERIC
Sequence Type COMPLETE
Record UNII
4F4X42SYQ6
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
RITUXIMAB (GENETICAL RECOMBINATION)
JAN  
Preferred Name English
RITUXIMAB
EMA EPAR   HSDB   INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
IDEC-C 2B8
Code English
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Common Name English
RITUXIMAB [HSDB]
Common Name English
Rituximab [WHO-DD]
Common Name English
RITUXIMAB [MART.]
Common Name English
RITUXIMAB [MI]
Common Name English
GP2013
Code English
IDEC-102
Code English
RITUXAN HYCELA COMPONENT RITUXIMAB
Brand Name English
RITUXIMAB [USAN]
Common Name English
RITUXIMAB [EMA EPAR]
Common Name English
USP MAB 001, MONOCLONAL IGG1 [USP-RS]
Common Name English
RITUXIMAB [VANDF]
Common Name English
rituximab [INN]
Common Name English
GP-2013
Code English
RITUXIMAB [JAN]
Common Name English
RITUXIMAB [PURPLE BOOK CDER]
Common Name English
IDEC102
Code English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS MABTHERA (AUTHORIZED: ARTHRITIS, RHEUMATOID)
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
EMA ASSESSMENT REPORTS MABTHERA (AUTHORIZED: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL)
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
FDA ORPHAN DRUG 177603
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
FDA ORPHAN DRUG 923822
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
NDF-RT N0000175078
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
FDA ORPHAN DRUG 781520
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
FDA ORPHAN DRUG 465014
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
FDA ORPHAN DRUG 840621
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
FDA ORPHAN DRUG 542416
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
WHO-VATC QL01XC02
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
NCI_THESAURUS C129822
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
EMA ASSESSMENT REPORTS MABTHERA (AUTHORIZED: LYMPHOMA, NON-HODGKIN)
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
FDA ORPHAN DRUG 79793
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
FDA ORPHAN DRUG 546516
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
LIVERTOX NBK548249
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
FDA ORPHAN DRUG 922222
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
FDA ORPHAN DRUG 216305
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
NCI_THESAURUS C141215
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
NDF-RT N0000175657
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
FDA ORPHAN DRUG 155102
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
FDA ORPHAN DRUG 545616
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
WHO-ATC L01XC02
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
FDA ORPHAN DRUG 529816
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
EU-Orphan Drug EU/3/17/1869
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
Code System Code Type Description
IUPHAR
6780
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY
MERCK INDEX
m9637
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY Merck Index
SMS_ID
100000089292
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY
DRUG BANK
DB00073
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY
RXCUI
2273510
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
ALTERNATIVE
JAPANESE REVIEW
RITUXAN
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY APPROVED AUGUST 2014
DAILYMED
4F4X42SYQ6
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201576
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY
WIKIPEDIA
RITUXIMAB
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY
USAN
II-64
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY
RS_ITEM_NUM
1445539
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY
NCI_THESAURUS
C1702
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY
INN
7609
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY
CAS
174722-31-7
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY
RXCUI
121191
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY RxNorm
EVMPD
SUB12570MIG
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY
MESH
C092560
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY
LACTMED
Rituximab
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY
EPA CompTox
DTXSID5040910
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY
FDA UNII
4F4X42SYQ6
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY
RXCUI
2105824
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
ALTERNATIVE
DRUG CENTRAL
4975
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY
JAPANESE REVIEW
ROMIPLATE
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY APPROVED JANUARY 2011
HSDB
7455
Created by admin on Mon Mar 31 18:48:10 GMT 2025 , Edited by admin on Mon Mar 31 18:48:10 GMT 2025
PRIMARY
From To
1_22 1_96
1_148 1_204
1_265 1_325
1_371 1_429
3_23 3_87
3_133 4_193
2_224 3_213
2_22 2_96
2_148 2_204
2_265 2_325
2_371 2_429
3_23 3_87
3_133 4_193
2_224 3_213
1_230 2_230
1_233 2_233
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_301
N 2_301
Related Record Type Details
RITUXIMAB-ABBS
BIOSIMILAR -> PARENT
RITUXIMAB-ARRX
SUB_CONCEPT->SUBSTANCE
RITUXIMAB-ARRX
BIOSIMILAR -> PARENT
MK-8808
SUB_CONCEPT->SUBSTANCE
B-LYMPHOCYTE ANTIGEN CD20
TARGET -> INHIBITOR
MK-8808
BIOSIMILAR -> PARENT
RITUXIMAB I-131
LABELED -> NON-LABELED
BI-695500
SUB_CONCEPT->SUBSTANCE
HIGH AFFINITY IMMUNOGLOBULIN GAMMA FC RECEPTOR I
TARGET -> SUBSTRATE
HIGH AFFINITY IMMUNOGLOBULIN GAMMA FC RECEPTOR I
TARGET -> AGONIST
B-LYMPHOCYTE ANTIGEN CD20
TARGET->LIGAND
RITUXIMAB (RITUXAN)
SUB_CONCEPT->SUBSTANCE
RITUXIMAB-ABBS
SUB_CONCEPT->SUBSTANCE
RITUXIMAB-PVVR
SUB_CONCEPT->SUBSTANCE
Related Record Type Details
RITUXIMAB
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO ACID SUBSTITUTION [1_1] [2_1] [3_1] [4_1] Q PIDOLIC ACID SZB83O1W42
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966